Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA4 | P22748 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23877329 | 0.91 | MEN1 (0.37) | GLP1RMEN1KMT2ACA12CA1 | |
| SCHEMBL26740079 | 0.85 | GLP1R (0.34) | GLP1RMEN1KMT2A | |
| SCHEMBL22996112 | 0.79 | GPBAR1 (0.30) | — | |
| SCHEMBL3538740 | 0.79 | MEN1 (0.39) | GLP1RMEN1KMT2ACA12CA1 | |
| SCHEMBL25583285 | 0.78 | GLP1R (0.36) | GLP1RMEN1KMT2ACA12CA1 | |
| SCHEMBL24849525 | 0.75 | — | — | |
| SCHEMBL16309272 | 0.73 | SLC1A2 (0.43) | KMT2A | |
| SCHEMBL15424356 | 0.73 | SLC1A2 (0.43) | KMT2A | |
| SCHEMBL26005443 | 0.72 | MEN1 (0.37) | GLP1RMEN1KMT2ACA12CA1 | |
| SCHEMBL19935469 | 0.72 | SLC6A2 (0.31) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021178607-A1 | COMPLEMENT COMPONENT C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING COMPLEMENT COMPONENT C3-ASSOCIATED DISEASES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-09-10 | — | — | WO | disclosed |